pre-update Archives

On-Demand Webinar

Overview of SNDS and the key working practices to access the database and ongoing SNDS developments

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 25 日

On-Demand Webinar

PBPK modeling approaches to assess risks associated with bioequivalence in drug development

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting…

Jim Gallagher2021 年 5 月 19 日

Blog

Why Your Regulatory Writers Need eCTD Authoring Templates

If you’ve heard about eCTD authoring template suites before, but you’re not sure what they…

Certara2021 年 5 月 14 日

Publication

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate

As model‐informed drug development becomes an integral part of modern approaches to the discovery of…

Jim Gallagher2021 年 5 月 13 日

Publication

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

Perhaps the most important lesson learned from the COVID‐19 pandemic is that of preparedness. Enhanced…

Jim Gallagher2021 年 5 月 11 日

Brochure

Early Engagement with HTA Bodies

In-depth guide to successful early HTA engagement.

Jim Gallagher2021 年 5 月 10 日

On-Demand Webinar

Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)

Watch this presentation to learn • Overview of the SNDS and the key working practices…

Jim Gallagher2021 年 5 月 7 日

Blog

Maximizing Oligonucleotide Therapeutic Development: How They Work

This is the first of three blog posts discussing best practices for developing oligonucleotides. Interest…

Certara2021 年 5 月 7 日

网络研讨会点播

The Wizard of Oligos: There’s no place like having a successful drug development program!

Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…

Jim Gallagher2021 年 4 月 30 日

On-Demand Webinar

基因疗法治疗罕见病的希望与陷阱

The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…

Jim Gallagher2021 年 4 月 29 日

pre-update

Overview of SNDS and the key working practices to access the database and ongoing SNDS developments

PBPK modeling approaches to assess risks associated with bioequivalence in drug development

Why Your Regulatory Writers Need eCTD Authoring Templates

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

Early Engagement with HTA Bodies

Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)

Maximizing Oligonucleotide Therapeutic Development: How They Work

The Wizard of Oligos: There’s no place like having a successful drug development program!

基因疗法治疗罕见病的希望与陷阱

订阅时事通讯

快捷链接

解决方案

联系我们